Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Conclusions: This study showed that cPD-L1 testing is feasible, with chemotherapy influencing PD-L1 plasma levels. The possibility of using such test for predicting or monitoring the effect of immunotherapy or combination of chemotherapy and immunotherapy warrant further investigations.
PMID: 29707129 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study